CLINICAL TRIALS PROFILE FOR MUTAMYCIN

All Clinical Trials for MUTAMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003018 ↗	S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00003018 ↗	S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer	Completed	Southwest Oncology Group	Phase 2	1997-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00734994 ↗	Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer	Completed	Mark Dewhirst	Early Phase 1	2008-04-01	Hypothesis: In selected patients external hyperthermia will be used in combination with intravesical Mitomycin-C (MMC) to treat recurrent transitional cell carcinoma (TCC) of the bladder after local resection and standard adjuvant therapy and thus prevent or delay recurrence and the need for radical cystectomy.
NCT01004978 ↗	Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2009-10-28	This randomized phase III trial studies chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, mitomycin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoembolization kills tumor cells by carrying drugs directly into blood vessels near the tumor and then blocking the blood flow to allow a higher concentration of the drug to reach the tumor for a longer period of time. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving chemoembolization together with sorafenib tosylate is more effective than chemoembolization alone in treating patients with liver cancer.
NCT01017640 ↗	Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors	Completed	National Cancer Institute (NCI)	Phase 1	2009-10-01	This phase I trial studies the side effects and best dose of veliparib when given with or without mitomycin C in treating patients with solid tumors that have spread to other places in the body, cannot be removed by surgery or have come back. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with mitomycin C may kill more tumor cells.
NCT02199327 ↗	Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia	Completed	Instituto Mexicano del Seguro Social	Phase 4	2014-05-01	The purpose of this study is to evaluate the therapeutic efficacy of interferon alfa 2b and topical mitomycin C in patients with diagnosis of conjunctival-corneal intraepithelial neoplasia.

Clinical Trial Conditions for MUTAMYCIN

Condition Name

Condition Name for MUTAMYCIN
Intervention	Trials
Stage III Bladder Cancer AJCC v8	3
Stage IIIA Bladder Cancer AJCC v8	3
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall	2
Bladder Urothelial Carcinoma	2

Condition MeSH

Condition MeSH for MUTAMYCIN
Intervention	Trials
Carcinoma	7
Urinary Bladder Neoplasms	5
Carcinoma, Transitional Cell	4
Fever	3

Clinical Trial Locations for MUTAMYCIN

Trials by Country

Trials by Country for MUTAMYCIN
Location	Trials
United States	191
Mexico	1

Trials by US State

Trials by US State for MUTAMYCIN
Location	Trials
California	6
Minnesota	6
Texas	6
Ohio	6
Michigan	6

Clinical Trial Progress for MUTAMYCIN

Clinical Trial Phase

Clinical Trial Phase for MUTAMYCIN
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2	9

Clinical Trial Status

Clinical Trial Status for MUTAMYCIN
Clinical Trial Phase	Trials
Completed	5
Recruiting	4
Not yet recruiting	3

Clinical Trial Sponsors for MUTAMYCIN

Sponsor Name

Sponsor Name for MUTAMYCIN
Sponsor	Trials
National Cancer Institute (NCI)	11
Mayo Clinic	2
ECOG-ACRIN Cancer Research Group	1

Sponsor Type

Sponsor Type for MUTAMYCIN
Sponsor	Trials
Other	12
NIH	11

Mutamycin (mitomycin) Clinical Trials Update, Market Analysis, and Projection

Last updated: May 9, 2026

Mutamycin is a topical oncology drug name used in some jurisdictions as a brand for mitomycin. Public clinical development and market data are sparse and fragmented across geographies because the underlying active ingredient (mitomycin, an older cytotoxic antibiotic) is widely available in generics and compounded formulations. The result is that trial registries, labeling, and commercial datasets often do not align to a single “Mutamycin” product identity, which limits the ability to produce a single, clean, company-grade development and revenue forecast for the specific brand name.

Is Mutamycin actively in late-stage clinical development?

What do registries show for “Mutamycin” as a distinct program?

No consistent, product-unique late-stage program (Phase 3 or pivotal Phase 2) is identifiable from public registries under “Mutamycin” as a stand-alone development entity. Across public sources, mitomycin trials commonly appear under “mitomycin” or variant spelling, not “Mutamycin,” and older studies predominate.

What is the practical implication for an R&D or investment view?

• Late-stage execution risk is high to assess for “Mutamycin” specifically because most modern activity is tied to mitomycin broadly, to device-or-procedure combinations, or to generic/local formulations.
• “Mutamycin” should be treated as an active-ingredient ecosystem asset, not as a clean branded pipeline line, unless a specific sponsor, formulation, and indication are defined in the filing or registry record.

Which indications drive mitomycin use today, and how does that shape “Mutamycin” commercialization?

Mitomycin’s clinical and commercial reality is indication- and setting-driven. Typical value pockets include oncology and surgical/procedural contexts where mitomycin is used as an anti-proliferative cytotoxic.

Common clinical/market-adjacent use areas (active ingredient level)

• Bladder cancer intravesical therapy (mitomycin-based regimens)
• Ocular surgery adjuncts (mitomycin use in ophthalmic procedures)
• Other localized oncology or wound/repair-adjunct uses, depending on jurisdiction and formulation

Because commercial availability is largely generic, pricing power and sales growth usually track:

1. local regulatory access and reimbursement,
2. procurement channel dynamics,
3. procedural volumes and uptake of mitomycin-based approaches,
4. competition from alternative cytotoxics and adjuncts.

What is the current competitive landscape versus “Mutamycin”?

How competition typically manifests

For an older cytotoxic, “Mutamycin” competition is usually not a like-for-like branded pipeline fight. It is a substitution and supply chain fight:

• Generics of mitomycin
• Alternative intravesical cytotoxics (where used)
• Procedural alternatives (especially in ophthalmology-adjunct settings)
• Compounding and distribution of active ingredient in regions with looser brand capture

What that means for market projection

Market growth for “Mutamycin” is constrained by:

• low differentiation (same active ingredient),
• procurement-led purchasing,
• margin pressure from generics,
• limited expansion unless a new formulation, dosing, or combination gets accepted with differentiation.

What do we project for “Mutamycin” sales and growth?

No single, authoritative public dataset ties global revenue to the brand name “Mutamycin.” A defensible projection therefore depends on treating “Mutamycin” as mitomycin under a brand wrapper in limited markets, which is not sufficiently supported by complete public financial disclosures.

Projection framework (active ingredient driven, brand-capture dependent)

To build a forecast you need three inputs:

• Indication demand proxy (procedure volumes or incidence-based treatment demand)
• Pricing proxy (net realized price for branded vs generic mix)
• Share of wallet (how much of mitomycin use a given “Mutamycin” label captures)

Because those brand-specific inputs are not consistently disclosed publicly for “Mutamycin,” a hard revenue forecast cannot be produced from verified sources.

What does the clinical and regulatory path look like if “Mutamycin” seeks differentiation?

If “Mutamycin” is positioned as more than a brand wrapper, differentiation options generally fall into one or more of these buckets:

• Formulation differentiation (e.g., sustained-release, stability improvements, novel excipients)
• Combination differentiation (new companion drug or procedure protocol)
• Delivery differentiation (device-guided delivery, catheter-based protocols, ocular adjunct delivery systems)
• Line extension via new indication or biomarker-selected population

In older cytotoxics, the most credible “new value” often comes from formulation and delivery rather than novel mechanism.

Clinical trial update summary (what is actionable right now)

What is known from public development records

• Public late-stage development for “Mutamycin” as a distinct branded asset is not clearly established.
• Most observable clinical activity is anchored to mitomycin with earlier-generation evidence, investigator-led studies, or region-specific use.

Actionable takeaways for an R&D program

• If the goal is to invest in “Mutamycin” as a pipeline asset, the dominant workstream is evidence mapping: confirm the specific formulation, dosage form, comparator, and sponsor identity tied to “Mutamycin” in each target market.
• If the goal is commercialization, brand capture strategy is the primary lever because generic competition typically compresses margin and reduces sustained pricing power.

Market analysis: sizing constraints and what can be projected from verified data

A quantified market size, CAGR, and 5-year projection for “Mutamycin” cannot be produced from public sources under the brand name alone without generating non-verifiable estimates. The underlying active ingredient market is also difficult to map because mitomycin revenue is often split across generic accounts, product formats, and local labeling.

Key Takeaways

• “Mutamycin” lacks an identifiable, registry-clean, late-stage branded clinical pipeline in public records; observed development maps more reliably to “mitomycin” than to the brand name.
• Commercial upside for a brand wrapper is usually constrained by generic mitomycin substitution and procurement-driven purchasing.
• A credible forecast requires brand-specific capture rates by geography and indication, but public disclosures do not support a verified, quantified “Mutamycin”-only revenue model.

FAQs

1) Is Mutamycin in Phase 3 right now?

Publicly visible records do not show a clear, product-unique Phase 3 program for “Mutamycin” as a branded entity distinct from mitomycin broadly.

2) What indications matter most for Mutamycin/mitomycin commercial demand?

Demand is typically driven by localized oncology use and procedure-based settings where mitomycin is used as an anti-proliferative cytotoxic adjunct.

3) Can a brand wrapper around mitomycin create pricing power?

In most jurisdictions, generics and alternative cytotoxics limit durable pricing power unless the brand has formulation, delivery, or protocol differentiation.

4) How should investors think about “Mutamycin” market projection?

Treat it as an active-ingredient market with brand capture dependency rather than as a standalone growth pipeline, unless a specific differentiated formulation is documented with labeled use and sponsor support.

5) Where can differentiation come from for an older mitomycin product?

Formulation, delivery, and protocol-combination differentiation are the most plausible routes that create defensible differentiation against generics.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] FDA. Drug Database (mitomycin-related entries). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] EMA. European public assessment reports and product information for mitomycin-containing medicinal products. https://www.ema.europa.eu/
[4] World Health Organization. WHO Model Lists of Essential Medicines (mitomycin-related entries where applicable). https://list.essentialmedicines.org/